



Fax completed form to: (855) 840-1678
 If this is an URGENT request, please call (800) 882-4462
 (800.88.CIGNA)

Vyepti (eptinezumab-jjmr)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations, we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed. *		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication requested:			ICD10:		
<input type="checkbox"/> Vyepti 100mg/ml vial <input type="checkbox"/> other (please specify):					
Directions for use:		Dosing and Quantity:		Duration of therapy:	
Frequency of therapy:					
Where will this medication be obtained?					
<input type="checkbox"/> Orsini Specialty Pharmacy <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Other (please specify):			<input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Physician's office stock (billing on a medical claim form)		
Facility and/or doctor dispensing and administering medication:					
Facility Name:		State:	Tax ID#:		
Address (City, State, Zip Code):					
Where will this drug be administered?					
<input type="checkbox"/> Patient's Home <input type="checkbox"/> Hospital Outpatient			<input type="checkbox"/> Physician's Office <input type="checkbox"/> Other (please specify):		
<i>NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.</i>					
Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? <input type="checkbox"/> Yes <input type="checkbox"/> No (provide medical necessity rationale):					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
What is your patient's diagnosis?					
<input type="checkbox"/> Acute Treatment of Migraine <input type="checkbox"/> Cluster Headache, Treatment or Prevention <input type="checkbox"/> Migraine Headache Prevention <input type="checkbox"/> All other indications or diagnoses					

Clinical Information

Is the requested medication to be used in combination with another calcitonin gene-related peptide (CGRP) inhibitor being prescribed for migraine headache prevention? CGRP inhibitors that are indicated for migraine headache prevention include Aimovig (erenumab-aooe subcutaneous injection), Ajovy (fremanezumab-vfrm subcutaneous injection), Emgality (galcanezumab-gnlm subcutaneous injection), and Qulipta (atogepant tablets). Yes No

Is the requested medication to be used in combination with Nurtec ODT (rimegepant sulfate orally disintegrating tablet) when used as a preventive treatment of migraine? Yes No

Does/Did the patient have greater than or equal to 4 (four) migraine headache days per month (prior to initiating a migraine-preventative medication)? Yes No

Is the patient currently taking Vyepti? Yes No

(if yes) Has the patient had a significant clinical benefit from the medication as determined by the prescriber? Note: Examples of significant clinical benefit include a reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Vyepti was initiated. Yes No

(if currently taking) Has the patient been receiving samples or coupons or other types of waivers in order to obtain Vyepti? Yes No

Which of the following has the patient tried? Check all that apply.

- Aimovig (erenumab-aooe) [requires prior authorization]
- Ajovy (fremanezumab-vfrm) [requires prior authorization]
- Emgality (galcanezumab-gnlm) [requires prior authorization]
- Qulipta (atogepant) [requires prior authorization]

For those drugs checked above, has the patient had inadequate efficacy or significant intolerance to them, according to the prescriber? Yes No

Additional Pertinent Information:

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v050126

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005